MedTrace Logo

Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034

NCT00358384 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-11-13

No results posted yet for this study

Summary

This study is an exploratory study to evaluate the effectiveness, safety and tolerability of three concentrations of GW786034 ointment following treatment to small areas of stable psoriatic plaques. Dosing will proceed using a microplaque approach, where small volumes of ointment will be applied under full occlusion to representative psoriatic plaques. The effectiveness of topical GW786034 treatments and controls will be explored using visual intensity assessments in addition to dermal imaging and histological surrogates of disease activity.

Conditions

Interventions

DRUG

Pazopanib

Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.

DRUG

Pazopanib vehicle

Pazopanib vehicle will be given to subjects.

DRUG

Betamethasone valerate

Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.

DRUG

Calcipotriol

Calcipotriol ointment with 0.005 percent concentration will be given to subjects.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-26
Primary Completion
2006-02-24
Completion
2006-02-24

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358384 on ClinicalTrials.gov